The fully integrated, pre-qualified, pre-installed aseptic filling facility can be shipped globally for drug development and the manufacturing of personalized medicines and clinical trial supplies.
Vanrx Pharmasystems, a sterile filling solutions company based in Canada, and G-CON Manufacturing, a College Station, TX-based cleanroom solutions company, announced on Jan. 20, 2020 that they are launching the Microcell POD, a turnkey facility for aseptic filling of advanced therapies.
Requiring a lead time of only three months, the new facility features Vanrx’s Microcell Vial Filler, which will be installed inside G-CON’s prefabricated cleanroom POD, a Vanrx press release said. The fully integrated, pre-qualified, pre-installed aseptic filling facility can be shipped globally, making it ideal for drug development and the manufacturing of personalized medicines and clinical trial supplies.
“Companies making targeted drug products including gene therapies, mRNA, and personalized cancer vaccines have a lot of problems to solve in bringing these new modalities to market,” said Chris Procyshyn, CEO and co-founder of Vanrx, in the press release. “It makes sense to combine the Microcell with the G-CON’s POD products because it provides certainty of performance and speed to market, while automating the crucial step of aseptic processing within an agile, completely closed system.”
“Our new POD product is standardized and fully designed to fulfill the delivery time need. Moreover, filling capacity is and has been a major bottleneck, so G-CON joined forces with the Vanrx team to create a fully functional, prequalified filling package for our customers,” added Maik Jornitz, president and CEO, G-CON, in the press release. “We are very happy to have the ability to supply a key critical manufacturing step as a drop-ship product to the industry.”
Source: Vanrx
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.